Targets › JAK2
24 programs from 23 companies in 246 trials: 109 Phase 2, 58 Phase 1, 56 Phase 3, 23 Phase 4; Immunology, Oncology, Other; next expected readout Nov 2026.
Non-membrane spanning protein tyrosine kinase that phosphorylates type I receptors such as growth hormone (GHR), prolactin (PRLR), leptin (LEPR), erythropoietin (EPOR), thrombopoietin receptor (MPL/TPOR); or type II receptors including IFN-alpha, IFN-beta, IFN-gamma and multiple interleukins. Functionally, plays a pivotal role in signal transduction and is involved in various processes such as cell growth,…. (UniProt, O60674)
Open in Phaseline: the race on JAK2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Takeda | Tofacitinib Janus Kinase (JAK) inhibitor | JAK3, JAK1, JAK2, TYK2 | Phase 4 | Ulcerative Colitis; Rheumatoid Arthritis; Axial Spondyloarthritis; Oral Lichen Planus … | Jul 2027 |
| Eisai | Filgotinib Maleate Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase TYK2 inhibitor | JAK1, JAK2, TYK2, JAK3 | Phase 4 | Ulcerative Colitis | Nov 2027 |
| Incyte | Ruxolitinib Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor | JAK1, JAK2, JAK3, TYK2 | Phase 3 | NonSegmental Vitiligo; Hidradenitis Suppurativa; Atopic Dermatitis; Graft-versus-host Disease (GVHD) … | Nov 2026 |
| AbbVie | Upadacitinib Tyrosine-protein kinase TYK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor; Tyrosine-protein kinase JAK2 inhibitor | TYK2, JAK3, JAK2, JAK1 | Phase 3 | Atopic Dermatitis; Systemic Lupus Erythematosus; Ulcerative Colitis (UC); Crohn's Disease … | Nov 2026 |
| LEO Pharma | Delgocitinib Janus Kinase (JAK) inhibitor | JAK3, JAK1, JAK2, TYK2 | Phase 3 | Lichen Sclerosus; Palmoplantar Pustulosis; Central Centrifugal Cicatricial Alopecia; Vitiligo | Dec 2026 |
| Chia Tai Tianqing Pharmaceutical Group | TQ05105 Tablets (Rovadicitinib Tablets) Janus kinase 1 (JAK1), Janus kinase 2 (JAK2), and Rho-associated coiled-coil containing pr | JAK1, JAK2, ROCK2 | Phase 3 | Graft-versus-host Disease; Chronic Graft Versus Host Disease; Myelofibrosis | Dec 2026 |
| Swedish Orphan Biovitrum | Pacritinib Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor; Activin receptor type-1 inhibitor | JAK2, FLT3, ACVR1, IRAK1 | Phase 3 | Primary Myelofibrosis; VEXAS; Myelofibrosis; Acute Myeloid Leukemia … | Dec 2026 |
| Pfizer | tofacitinib Janus Kinase (JAK) inhibitor | JAK3, JAK1, JAK2, TYK2 | Phase 3 | Ulcerative Colitis | Mar 2027 |
| Chengdu Zenitar Biomedical Technology | Flonoltinib Maleate JAK1/JAK2 inhibitor | JAK1, JAK2 | Phase 3 | MF; MF,PMF,PPV-MF,PET-MF; Polycythemia Vera (PV) | May 2027 |
| Sun Pharmaceutical Industries | Deuruxolitinib Phosphate (CTP-543) Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor | JAK1, JAK2, JAK3, TYK2 | Phase 3 | Alopecia Areata | May 2027 |
| Alfasigma | Filgotinib Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase TYK2 inhibitor | JAK1, JAK2, TYK2, JAK3 | Phase 3 | Polyarticular Course Juvenile Idiopathic Arthritis; Juvenile Idiopathic Arthritis (JIA); Ulcerative Colitis; Axial Spondyloarthritis … | Jun 2027 |
| Eli Lilly | Baricitinib (LY3009104) Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor | JAK1, JAK2 | Phase 3 | Systemic Juvenile Idiopathic Arthritis; Areata Alopecia; Diabetes Mellitus, Type 1; Uveitis … | Mar 2028 |
| Suzhou Zelgen Biopharmaceuticals | Jaktinib Hydrochloride Tablet JAK inhibitor | JAK1, JAK2, JAK3 | Phase 3 | Atopic Dermatitis | – |
| GSK | Momelotinib Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Activin receptor type-1 inhibitor | JAK1, JAK2, ACVR1 | Phase 2 | Primary Myelofibrosis; Myelodysplastic Syndromes; VEXAS Syndome; Myeloid Leukemia … | Dec 2026 |
| M.D. Anderson Cancer Center | Ruxolitinib Phosphate Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor | JAK1, JAK2, JAK3, TYK2 | Phase 2 | Splenomegaly; AML; Chronic Lymphocytic Leukemia; T-cell Prolymphocytic Leukemia … | Jan 2027 |
| Fudan University | SHR-0302 JAK inhibitor | JAK1, JAK2, JAK3 | Phase 2 | Relapsed/Refractory Peripheral T Cell Lymphoma | Feb 2027 |
| City of Hope Medical Center | Ruxolitinib Phosphate Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor | JAK1, JAK2, JAK3, TYK2 | Phase 2 | Acute Lymphoblastic Leukemia; Follicular Helper T-Cell Lymphoma; Hematopoietic and Lymphatic System Neoplasm | Mar 2027 |
| Theradex | Pacritinib Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor; Activin receptor type-1 inhibitor | JAK2, FLT3, ACVR1, IRAK1 | Phase 2 | Leukemia, Myelomonocytic, Chronic | Jul 2028 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | Ivarmacitinib JAK inhibitor | JAK1, JAK2 | Phase 2 | Esophageal Squamous Cell Carcinoma | Dec 2028 |
| Shixiu Wu | JAK Inhibitors Janus kinase inhibitors | JAK1, JAK2, JAK3, TYK2 | Phase 2 | Immune Checkpoint Inhibitors (ICI)-Related Dermatitis | – |
| Bristol-Myers Squibb | Fedratinib Tyrosine-protein kinase receptor FLT3 inhibitor; Tyrosine-protein kinase JAK2 inhibitor | FLT3, JAK2 | Phase 1 | Primary Myelofibrosis; Acute Myeloid Leukemia | Nov 2026 |
| AbbVie | Tofacitinib Janus Kinase (JAK) inhibitor | JAK3, JAK1, JAK2, TYK2 | Phase 1 | Healthy Volunteers | Dec 2026 |
| Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company | LY5830966 Type II JAK2 inhibitor | JAK2 | Phase 1 | Primary Myelofibrosis | Jun 2027 |
| First Affiliated Hospital of Zhejiang University | Gecacitinib (also known as Jaktinib) JAK inhibitor | JAK1, JAK2, JAK3 | Phase 1 | Acute Graft Versus Host Disease | Dec 2027 |
Myelofibrosis (10) Rheumatoid Arthritis (9) Primary Myelofibrosis (8) Atopic Dermatitis (7) Ulcerative Colitis (6) Acute Lymphoblastic Leukemia (6) Acute Myeloid Leukemia (5) Alopecia Areata (4) Rheumatoid Arthritis (RA (4) Vitiligo (4) Hidradenitis Suppurativa (4) Chronic Graft Versus Host Disease (3)
small molecule (22), mixed (2)
AbbVie (2) First Affiliated Hospital of Zhejiang University (1) Chia Tai Tianqing Pharmaceutical Group (1) Sun Pharmaceutical Industries (1) Alfasigma (1) Bristol-Myers Squibb (1) Takeda (1) Incyte (1) Chengdu Zenitar Biomedical Technology (1) Eli Lilly (1) LEO Pharma (1) Second Affiliated Hospital, Zhejiang University, School of Medicine (1) Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company (1) GSK (1) Eisai (1) Swedish Orphan Biovitrum (1) Theradex (1) City of Hope Medical Center (1) Shixiu Wu (1) M.D. Anderson Cancer Center (1)
JAK1 (20) JAK3 (15) TYK2 (12) FLT3 (3) ACVR1 (3) IRAK1 (2) ROCK2 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.